Get started
Author

Scott D. Bercury

Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment
2003 · Andrew M Tager, Shannon K Bromley, et al. · Nature Immunology · 419
Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10
2004 · Andrew M. Tager, Richard L. Kradin, et al. · American Journal of Respiratory Cell and Molecular Biology · 199
Bltr Mediates Leukotriene B4–Induced Chemotaxis and Adhesion and Plays a Dominant Role in Eosinophil Accumulation in a Murine Model of Peritonitis
2000 · Andrew M. Tager, Jennifer H. Dufour, et al. · The Journal of Experimental Medicine · 195
Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease
2009 · Yunxiang Zhu, Ji-Lei Jiang, et al. · Molecular Therapy · 177
PDF
Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy
2010 · Gregory D Hurlbut, Robin J Ziegler, et al. · Molecular Therapy · 142
Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8–mediated Hepatic Expression of α-galactosidase A
2006 · Robin J Ziegler, Maribeth Cherry, et al. · Molecular Therapy · 89
Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
2012 · Mario A. Cabrera-Salazar, Matthew DeRiso, et al. · PLoS ONE · 80
PDF
Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease
2011 · Karen M. Ashe, Dinesh Bangari, et al. · PLoS ONE · 72
Ability of Adeno-Associated Virus Serotype 8-Mediated Hepatic Expression of Acid α-Glucosidase to Correct the Biochemical and Motor Function Deficits of Presymptomatic and Symptomatic Pompe Mice
2008 · Robin J. Ziegler, Scott D. Bercury, et al. · Human Gene Therapy · 65
Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease
2010 · M.A. Cabrera-Salazar, S.D. Bercury, et al. · Experimental Neurology · 37
Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion
2011 · Robin J. Ziegler, Ernesto A. Salegio, et al. · Experimental Neurology · 35
Evaluation of Systemic Follistatin as an Adjuvant to Stimulate Muscle Repair and Improve Motor Function in Pompe Mice
2010 · Joseph W Foley, Scott D Bercury, et al. · Molecular Therapy · 30
PDF
Molecular analysis of the Doppia transposable element of maize
2001 · Scott D. Bercury, Tadas Panavas, et al. · Plant Molecular Biology · 18
WS19.01 Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of ΔF508-CFTR
2025 · G. Hurlbut, S. Altmann, et al. · Journal of Cystic Fibrosis · 2
EPS3.10 Novel CFTR modulator combinations directly address the ΔF508-CFTR NBD1 stability defect and enable full CFTR correction
2023 · G. Hurlbut, S. Altmann, et al. · Journal of Cystic Fibrosis · 2
PDF
662 Novel cystic fibrosis transmembrane conductance regulator modulator combinations that address the first nucleotide binding domain defect central to ΔF508 dysfunction enable full correction of cystic fibrosis transmembrane conductance regulator
2022 · G. Hurlbut, S. Altmann, et al. · Journal of Cystic Fibrosis · 2
PDF
289 Beyond SION-638: a novel series of highly potent stabilizers of the first nucleotide binding domain enables full correction of ΔF508-CFTR in a dual combination with Sionna CFTR modulators, providing a path to wild-type function
2023 · G. Hurlbut, S. Altmann, et al. · Journal of Cystic Fibrosis · 1
PDF
The ΔF508 CFTR defect: molecular mechanism of suppressor mutation V510D and the contribution of transmembrane helix unraveling
2020 · Kailene S. Simon, Karthi Nagarajan, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Poster: 295Assessing the effect of NBD1 stabilizers SION-451 and SION-719 in combination with other CFTR modulators on primary human bronchial epithelial cells from F508del/F508del and F508del/null donors
2026 · S. Altmann, S. Bercury, et al. · Journal of Cystic Fibrosis
Clinical-stage NBD1 stabilizers can increase F508del-CFTR protein half-life to wild-type levels when used alone or in combination with other CFTR modulators
2026 · S. Bercury, A. Madanjian, et al. · Journal of Cystic Fibrosis
303 Small molecule stabilizers of CFTR NBD1 can increase the protein half- life of the apical glycoform of F508del-CFTR to that of wild-type CFTR
2025 · G. Hurlbut, S. Bercury, et al. · Journal of Cystic Fibrosis
The Lysophosphatidic Acid Receptor LPA1 Links Pulmonary Fibrosis to Lung Injury by Mediating Fibroblast Recruitment and Vascular Leak
2012 · Andrew M. Tager, Peter LaCamera, et al. · Proceedings of the American Thoracic Society
M.P.5.10 Efforts to enhance AAV8-mediated gene therapy of Pompe disease
2007 · R. Ziegler, S. Bercury, et al. · Neuromuscular Disorders
33. Systemic Delivery of AAV8/DC190-GAA to Pompe Mice Normalizes Muscle Pathology and Corrects Motor Function Deficits
2006 · R.J. Ziegler, M.A. Zhao, et al. · Molecular Therapy
PDF
Works count: 24
Citation count: 1,566
H-index: 13
I10-index: 13
Year
Topic
Type